Fig. 1

AT-001 binds AR with no adverse effects. a Molecular docking of AT-001 in the binding pocket of AR. b–g Aldose reductase activity (b), cardiac sorbitol levels (c), random blood glucose levels (d), body weight (e), whole-body fat mass (f), and whole-body lean mass (g) of C57BL/6J mice with experimental DbCM treated with either vehicle control (VC) or AT-001 (40 mg/kg/day) for 3 weeks (n = 5). Values represent means ± SEM. Differences were determined using an unpaired two-tailed Student’s t-test